MedTrace Logo

Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases

NCT04413292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2020-06-04

No results posted yet for this study

Summary

Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis. Fibulin-3, a matrix glycoprotein, was recently presented as a promising novel biomarker for malignant pleural mesothelioma. The aim of this study was to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases.

Patients and methods: The study included 73 patients, with various benign and malignant respiratory diseases. For validation of the data, a control group including 20 healthy subjects was chosen. The clinical and radiological assessments of the included individuals were done. The serum survivin and fibulin-3 levels were measured using ELISA assays kits, while their local expressions in the lung and pleura were assessed using western blot analysis.

Conditions

  • Bronchial Neoplasm Benign

Interventions

DIAGNOSTIC_TEST

ELISA assays and Westren blot analysis of survivin and fibulin-3 expression

expression analysis of biomarkers

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-12-30
Completion
2020-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04413292 on ClinicalTrials.gov